-
公开(公告)号:EP3811968A1
公开(公告)日:2021-04-28
申请号:EP20208197.2
申请日:2010-03-03
申请人: ELI LILLY AND CO.
发明人: POHL, Roderike , STEINER, Soloman S. , HAUSER, Robert , LI, Ming
摘要: Injectable insulin formulations with improved stability and rapid onset of action are described herein. The formulations may be for subcutaneous, intradermal or intramuscular administration. In the preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin in combination with a chelator and dissolution agent, and optionally additional excipients. In the preferred embodiment, the formulation contains human insulin, a zinc chelator such as EDTA and a dissolution agent such as citric acid or sodium citrate. These formulations are rapidly absorbed into the blood stream when administered by subcutaneous injection.
-
2.
公开(公告)号:EP3827813A1
公开(公告)日:2021-06-02
申请号:EP20215156.9
申请日:2013-04-16
申请人: ELI LILLY AND CO.
发明人: POHL, Roderike , HAUSER, Robert , LI, Ming , WILSON, Bryan R.
摘要: Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid ("EDTA"), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations by mixing them with a vial containing dry powder excipients that accelerate their absorption. Devices for mixing excipient and insulin together at the time of administration, while minimizing residence time of the mixture, are also described.
-